The MIRAGE trial is the only randomized trial to date comparing these state-of-the-art technologies in radiation oncology. It ...

Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -- Two new ...

AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024; formal interim analysis of disease-free survival (“DFS”) expected in H1 2025 Poster presentation at the Society ...

New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...